Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Ligand Pharmaceuticals (Nasdaq: LGND) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) on the same day to discuss the results and provide a business update. The call will be accessible via phone for U.S. & Canada (800-715-9871) and International (646-307-1963) participants using conference ID 8755336. A live webcast and replay will also be available.
Ligand Pharmaceuticals (Nasdaq: LGND) ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per giovedì 27 febbraio 2025, prima dell'apertura dei mercati statunitensi. L'azienda ospiterà una conferenza telefonica e un webcast alle 8:30 a.m. ET (5:30 a.m. PT) lo stesso giorno per discutere i risultati e fornire un aggiornamento aziendale. La chiamata sarà accessibile via telefono per i partecipanti degli Stati Uniti e del Canada (800-715-9871) e per quelli internazionali (646-307-1963) utilizzando l'ID conferenza 8755336. Saranno disponibili anche un webcast dal vivo e una registrazione.
Ligand Pharmaceuticals (Nasdaq: LGND) ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para jueves 27 de febrero de 2025, antes de la apertura de los mercados en EE. UU. La compañía llevará a cabo una conferencia telefónica y un webcast a las 8:30 a.m. ET (5:30 a.m. PT) el mismo día para discutir los resultados y proporcionar una actualización empresarial. La llamada será accesible por teléfono para los participantes de EE. UU. y Canadá (800-715-9871) y para los internacionales (646-307-1963) utilizando el ID de conferencia 8755336. También habrá un webcast en vivo y una repetición disponible.
리간드 제약 (Nasdaq: LGND)는 2025년 2월 27일 목요일에 2024년 4분기 및 연간 재무 결과 발표를 예정하고 있습니다. 미국 시장이 열리기 전에 발표를 진행합니다. 회사는 같은 날 오전 8:30 ET(오전 5:30 PT)에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 전화 회의 및 웹캐스트를 개최할 예정입니다. 미국 및 캐나다 참가자는 전화(800-715-9871)로, 국제 참가자는 전화(646-307-1963)를 통해 회의 ID 8755336을 사용하여 참여할 수 있습니다. 라이브 웹캐스트와 재생도 제공될 예정입니다.
Ligand Pharmaceuticals (Nasdaq: LGND) a programmé l'annonce de ses résultats financiers pour le quatrième trimestre et l'année complète 2024 pour jeudi 27 février 2025, avant l'ouverture des marchés américains. L'entreprise tiendra une conférence téléphonique et un webcast le même jour à 8h30 ET (5h30 PT) pour discuter des résultats et fournir une mise à jour sur les activités. L'appel sera accessible par téléphone pour les participants des États-Unis et du Canada (800-715-9871) et pour les participants internationaux (646-307-1963) en utilisant l'ID de conférence 8755336. Un webcast en direct et une rediffusion seront également disponibles.
Ligand Pharmaceuticals (Nasdaq: LGND) hat die Bekanntgabe der finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Donnerstag, den 27. Februar 2025, vor der Eröffnung der US-Märkte angesetzt. Das Unternehmen wird am selben Tag um 8:30 Uhr ET (5:30 Uhr PT) eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu diskutieren und ein Unternehmensupdate zu geben. Die Konferenz ist telefonisch für Teilnehmer aus den USA und Kanada (800-715-9871) sowie international (646-307-1963) mit der Konferenz-ID 8755336 zugänglich. Ein Live-Webcast und eine Aufzeichnung werden ebenfalls verfügbar sein.
- None.
- None.
Conference Call and Webcast Information
| Date: | Thursday, February 27, 2025 |
|
|
Time: |
8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) |
|
|
| Conference Call: |
(800) 715-9871 ( |
(646) 307-1963 (International) |
|
Conference ID is 8755336 |
|
|
|
| Webcast: | Live and replay webcasts of the call are available here. |
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213638160/en/
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
Source: Ligand Pharmaceuticals Incorporated
FAQ
When will Ligand (LGND) release Q4 and full year 2024 earnings?
What time is Ligand's (LGND) Q4 2024 earnings call?
How can investors access Ligand's (LGND) Q4 2024 earnings call?
Will there be a replay available for Ligand's (LGND) Q4 2024 earnings call?
